key: cord-0711872-h0r99ngs
authors: L’Huillier, Arnaud G.; Meyer, Benjamin; Andrey, Diego O.; Arm-Vernez, Isabelle; Baggio, Stephanie; Didierlaurent, Arnaud; Eberhardt, Christiane S.; Eckerle, Isabella; Grasset-Salomon, Carole; Huttner, Angela; Posfay-Barbe, Klara M.; Royo, Irene Sabater; Pralong, Jacques A.; Vuilleumier, Nicolas; Yerly, Sabine; Siegrist, Claire-Anne; Kaiser, Laurent
title: Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
date: 2021-01-20
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.01.005
sha: c499e64bf305e10e978dc537de96b256372fc230
doc_id: 711872
cord_uid: h0r99ngs

OBJECTIVE: To longitudinally evaluate the persistence of humoral immunity up to six months in a cohort of hospital employees with mild COVID-19. METHODS: We measured anti-RBD, -N and neutralizing antibodies at one, three and six months after mostly mild COVID-19 in 200 hospital workers using commercial ELISAs and a surrogate virus neutralization assay. RESULTS: SARS-CoV-2-specific antibodies persisted in all participants up to 6 months. Anti-RBD geometric mean concentrations (GMCs) progressively increased between month one (74(.)2 U/ml [95%CI 62(.)7-87(.)8), three (103(.)2 U/ml [95%CI 87(.)9-121(.)2]; p<0(.)001), and six (123(.)3 U/ml [95%CI 103(.)4-147(.)0]; p<0(.)001) in the whole cohort. Anti-N antibodies were detectable in >97% at all times. Neutralizing antibodies were detectable in 99.5% (195/196) of participants at six months post infection. Their GMC progressively decreased between months one (20(.)1 AU/ml [95%CI 16(.)9-24(.)0]), three (15(.)2 AU/ml [95%CI 13(.)2-17(.)6]; p<0(.)001) and six (9(.)4 AU/ml [95%CI 7(.)7-11(.)4]; p<0(.)001). RBD-ACE2 inhibiting antibody titers and anti-RBD antibody concentrations strongly correlated at each timepoint (all r>0(.)86, p<0(.)001). Disease severity was associated with higher initial anti-RBD and RBD-ACE2 inhibiting antibody titers, but not with their kinetics. CONCLUSION: Neutralizing antibodies persisted at six months in almost all participants, indicating more durability than initially feared. Anti-RBD antibodies persisted better and even increased over time, possibly related to the preferential detection of progressively higher-affinity antibodies.

Most SARS-CoV-2-infected individuals present self-limited disease. Upon infection, SARS-CoV-2 elicits humoral responses, and within 3 weeks almost all infected patients develop antibodies against the receptor-binding (RBD), S1 and S2 domains of the 62 spike (S) glycoprotein as well as the nucleocapsid protein (N) [1] [2] [3] [4] [5] [6] . Most also develop neutralizing antibodies [3, [5] [6] [7] .

Characterizing the breadth and the persistence of humoral responses over time in non-hospitalised SARS-CoV-2 individuals is of 64 paramount importance in terms of public health, to assess the potential benefit of immunity and to design future preventive 65 interventions. Lyer et al. showed that antibodies against S-protein retained neutralizing capabilities and persisted up to 75 days 66 post infection in more than 95% of patients [6] . Recently, Gudbjartsson et al. showed that there was no sign of waning of antibody 67 levels up to four months after infection [8] . On the other hand, some studies suggest a reduction of neutralizing capabilities during 68 the early convalescent phase [9] . We have characterized humoral responses six months after the first pandemic wave in subjects 69 with mostly mild COVID-19, as well as the host factors and disease patterns that have been implicated in impacting these 70 responses [2, 3, 6, 9, 10] . 

RT-PCR and viral load at diagnosis: SARS-CoV-2 RT-PCR was performed according to manufacturers' instructions on various 82 platforms. Viral load (E-gene) was expressed in log 10 of RNA copies/ml as previously described [11] . Further details about RT-83 PCR and viral load are provided in the Supplementary Methods. 84 SARS-CoV-2 antibody detection: SARS-CoV-2 antibodies were measured using the quantitative Elecsys anti-RBD and semi-85 quantitative Elecsys anti-N (both measuring total immunoglobulin levels) on the cobas e801 analyzer (Roche Diagnostics 86 Rotkreuz, Switzerland) . Results for the quantitative Elecsys anti-RBD antibodies are reported as concentrations (U/ml) with a 87 manufacturer's cuf-off >0 . 8 U/ml considered as positive. Results for the Elecsys anti-N antibodies are reported as a cut-off index 88 (signal sample/cut-off or signal calibrator), with values >1 considered as positive. Quality controls and coefficients of variation for 89 both assays are provided in Table S1 .

J o u r n a l P r e -p r o o f Anti-RBD antibody responses. At one, three and six months, all participants had detectable anti-RBD antibodies ( Figure 2A ).

Anti-RBD GMCs increased progressively and significantly at each of the three visits ( 125 month six. Anti-RBD antibodies increased over time among the whole cohort ( Figure 3A ). At six months, 36 . 7% (72/196) of 126 participants showed anti-RBD values (U/ml) that were at least 2-fold higher than at one month, while only 4 . 6% (9/196) had 2-127 fold lower values, and anti-RBD antibodies remained stable (0 . 5-2 fold change) for 58 . 7% (115/196) of participants ( Figure S1A ).

In a latent growth model without covariates, anti-RBD concentrations increased with time ( neutralization test (PRNT) with a cut-off at 90% or 50% reduction (PRNT90 or PRNT50, respectively). Overall, we found a very 142 high correlation between sVNT and PRNT (r=0 . 936; p<0 . 0001), but also noticed that for low RBD-ACE2 inhibiting antibody 143 titers (AU/ml <5) the sVNT did not predict the presence of neutralizing antibodies accurately ( Figure S2 

The symptom density score was significantly and positively associated with the concentration of anti-RBD (p=0 . 001) and RBD-163 ACE2 inhibiting antibody titers (p=0 . 004) one month after diagnosis, indicating higher antibodies in those with more symptoms 164 (Table 3) . However, the symptom density score did not impact the kinetics of the anti-RBD and RBD-ACE2 inhibiting antibody 165 responses (Table 3 ). The inclusion of persistent symptoms (anosmia, disgueusia and fatigue) generated similar results (data not 166 shown). Similarly, analyses of specific symptoms individually (cough, fever) did not impact the kinetics of the anti-RBD and 167 RBD-ACE2 inhibiting antibody responses (data not shown). We observed faster anti-RBD increase in women compared to men 168 (p=0 . 010) ( 183 Therefore, the increase in signal in the RBD assay could reflect antibody affinity maturation over time while the total amount of 184 anti-RBD antibodies actually remains stable or even slightly decreases. Similar results were observed after yellow-fever vaccination, where affinity maturation increased over 6 to 9 months despite a slight decrease in serum neutralization titres [17] .

J o u r n a l P r e -p r o o f 8 Finally, a boosting effect secondary to re-exposure to SARS-CoV-2 is very unlikely to explain the increase in anti-RBD 187 concentrations seen in most participants, given the relatively low circulation of the virus between month 1 and month 6.

188 Thus, we interpret the strong persistence /increase of anti-RBD antibodies as reflecting the detection of progressively higher-189 affinity antibodies over time.

Interestingly, the kinetics of anti-N antibodies differed from those of anti-RBD, following the traditional pattern of an early peak 191 followed by a decline, thus suggesting differences in long-lived plasma cell activation by surface (RBD) or internal (N) antigens. 

In our dataset, there was a positive association between disease severity, expressed as a symptom density score, and initial anti-209 RBD and RBD-ACE2 inhibiting antibody titers. However, there was no association between symptom density score and the 210 evolution of anti-RBD and RBD-ACE2 inhibiting antibody titers over time, suggesting that disease severity impacts the initial 211 magnitude but not the persistence of antibodies. These data, which are in line with data showing weaker humoral responses among 212 pauci-or asymptomatic patients [2, 6, 9, 10] The dashed lines represent the respective assays cut-offs.

A comparison of four serological assays for 293 detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations

CoV-2 Antibodies in Persons with Mild Covid-19

Longitudinal dynamics of the 331 human B cell response to the yellow fever 17D vaccine

Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from 337 SARS-CoV infection

Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Clinical management of COVID-19 -interim guidance 27

Virological assessment of hospitalized 344 patients with COVID-2019

A neutralizing human antibody binds to the N-terminal domain 346 of the Spike protein of SARS-CoV-2

A human SARS-CoV neutralizing antibody against epitope on S2 348 protein

Validation and clinical evaluation of a SARS-350

CoV-2 Surrogate Virus Neutralisation Test (sVNT)

A SARS-CoV-2 surrogate virus neutralization test based on 353 antibody-mediated blockage of ACE2-spike protein-protein interaction

Median symptom density score (IQR), symptom-days# 36 (19-58) Symptoms frequency, n (%) days, median (IQR) n (%) kgs, median (IQR)

Symptom density score is the product of the total number of acute symptoms and the total duration (days) of each symptom

J o u r n a l P r e -p r o o f (n=5); leukemia (n=1); melanoma (n=1) **Psoriasis (n=2), hyperthydoidism (n=1); hypothyroidism (n=1); lupus (n=1), ankylosing spondylitis (n=1) ***Chronic obstructive pulmonary disease (n=1); emphysema (n=1); pulmonary sarcoidosis (n=1) ****Endometriosis (n=2); obstructive apnea (n=1); pacemaker (n=1) J o u r n a l P r e -p r o o f Excluded (n=2) Loss to follow-up (n=1) Likely false-positive SARS-CoV-2 RT-PCR (n=1)*